The French channel France 3 dedicated a report on BOYDSense, the Alpha MOS subsidiary specialized in medical applications, that works on a pain-free device to monitor glucose levels with exhaled breath.
The journalists also interviewed Pr. Pierre Gourdy, diabetes specialist within Toulouse CHU, who managed the a clinical study conducted on 130 patients with Type-2 diabetes.
See the replay on France 3 – August 30, 2023 (6:30 – Login required)
BOYDSense, Inc. is a medical technology company developing affordable, non-invasive tools for measuring critical biomarkers via exhaled breath. Its mission is to build the platform for anywhere, anytime biosignature capture and display to help consumers better manage their conditions. Breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using them to diagnose and monitor chronic diseases, such as diabetes. The BOYDSense platform will also allow consumers and healthcare providers to use breath as a non-invasive medium to detect and monitor diseases like cancer, obesity, asthma, and others. BOYDSense’s first product under development, the g-Sense Breath Meter, is an affordable handheld device that allows people with diabetes to accurately measure blood glucose values through breath-based VOCs without the cost, pain, and social stigma associated with conventional fingerstick glucose testing. BOYDSense is an Alpha MOS company, the leader in volatile organic compound analysis.
For more information, please visit: www.boydsense.com.